In This Article:
JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Pharvaris (PHVS) to $46 from $50 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.
Don't Miss our Black Friday Offers:
-
Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PHVS: